BioCentury
ARTICLE | Financial News

Regulus planning follow-on, adds options to Sanofi deal

June 27, 2013 12:45 AM UTC

MicroRNA company Regulus Therapeutics Inc. (NASDAQ:RGLS) proposed late Wednesday to raise up to $57.5 million in a follow-on underwritten by Lazard; Cowen; BMO Capital Markets; Needham; and Wedbush.

Separately, Regulus disclosed that last week it granted Sanofi (Euronext:SAN; NYSE:SNY) an exclusive option to license co-development and commercialization rights to undisclosed microRNA targets and biomarkers. In turn, Sanofi granted Regulus the exclusive option to license co-development and commercialization rights to microRNA-21 (miR-21) antagomirs to treat cancer and Alport syndrome, a genetic disorder characterized by end-stage kidney disease and hearing loss. Both options expire on Dec. 31. Regulus and Sanofi partnered in 2010 to discover, develop and commercialize microRNA therapeutics for up to four targets (see BioCentury, June 28, 2010). ...